GE to pay €150M for new biopharma campus in Ireland

GE BioPark mock up

GE is setting up a new site, to be known as “GE BioPark Cork,” as it looks to boost its off-the-shelf biomanufacturing facilities in Ireland.

The so-called BioPark is set to house around 500 new staffers when fully up and running, with most of these (400) coming from biotechs and pharmas and the rest employed by GE.

When the paperwork is out of the way, GE said it expects to start building around halfway through next year.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

The GE BioPark will also include its four fully equipped KUBio factories, owned by biopharma companies to help produce their meds, with GE “running centralised shared utilities and site services,” according to the company’s statement.

Ireland’s minister for Jobs, Enterprise and Innovation, Mary Mitchell O’Connor, said in the statement: “The biopharma industry makes a huge contribution to the Irish economy in terms of jobs and manufacturing exports, and is one of the fastest growing sectors. I am delighted that GE is making a significant investment in Cork. This is a further testament to our talented workforce. … I welcome GE's commitment to Ireland and wish them every success in the future.”

Kieran Murphy, CEO of GE Healthcare Life Sciences, added: “Pharma companies worldwide are racing to respond to patient needs with new life-changing biological medicines and GE is investing in technology and service solutions, as well as industry skills and expertise, to enable them to make and get their products to market more quickly. We are delighted to be investing once again in Ireland, where we have ourselves a long history of manufacturing our own medical imaging products.”

Suggested Articles

Matching the right patients to the right trials is a key piece of the recruitment puzzle. In oncology, it can be life and death.

U.K.-based CRO Sygnature Discovery is buying up fellow native life science services provider XenoGesis in order to boost its preclinical offerings.

PRA Health is tapping Deep Lens and the Microsoft Azure platform in matchmaking cancer patients to the right trials to speed up recruitment.